Tharakeswara Kumar Bathala MD, Presenter: Nothing to Disclose

Ajaykumar Chandralal Morani MD, Abstract Co-Author: Nothing to Disclose

Hyunseon C. Kang MD, PhD, Abstract Co-Author: Nothing to Disclose

Shiva Gupta MD, Abstract Co-Author: Nothing to Disclose

Dhakshina Moorthy Ganeshan MBBS, FRCR, Abstract Co-Author: Nothing to Disclose

Vikas Kundra MD, PhD, Abstract Co-Author: License agreement, Introgen Therapeutics Inc

1. Describe oncogenetics of ccRCC, with an emphasis on genetic pathways of ccRCC carcinogenesis. 2. Introduce Radiogenomics, an evolving science that links diagnostic imaging features to gene expression patterns. 3. Describe current and future clinical applications of oncogenomics and radiogenomics.  

1. Pathological Classification of RCC 2. Carcinogenesis of ccRCC 3. Genetic Pathways of Hereditary and Sporadic ccRCC 4. Phenotypic Heterogeneity (imaging features) of ccRCC in Correlation with Gene Expression 5. Genetic Pathways Affecting Current Targeted Therapies  

Recent advances in the understanding of molecular pathways underlying ccRCC has led to development of new therapies and imaging strategies. The role of radiology as essential link between oncogenetics has becomes more and more important in the era of personalized medicine. This exhibit will feature the information on the recent developments in oncogentics of ccRCC highlighting the importance of radiology (radiogenomics) in the changing landscape of ccRCC management.

Bathala, T, Morani, A, Kang, H, Gupta, S, Ganeshan, D, Kundra, V, Oncogenetics of Clear Cell Renal Cell Carcinoma (ccRCC) in the Era of Personalized Medicine: What Radiologist Needs to Know?.  Radiological Society of North America 2013 Scientific Assembly and Annual Meeting, December 1 - December 6, 2013 ,Chicago IL. http://archive.rsna.org/2013/13014659.html